Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in EnglandBusiness Wire • 01/31/25
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid PainkillerInvestors Business Daily • 01/31/25
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute PainBusiness Wire • 01/30/25
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decadesCNBC • 01/30/25
Investors who Lost Money on Vertex Pharmaceuticals Incorporated Should Contact Levi & Korsinsky About an Ongoing Investigation - VRTXAccesswire • 01/30/25
Vertex Pharmaceuticals Incorporated (VRTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky InvestigatesAccesswire • 01/28/25
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to DeclineZacks Investment Research • 01/27/25
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10Business Wire • 01/27/25
Investors who lost money on Vertex Pharmaceuticals Incorporated should contact Levi & Korsinsky about an ongoing investigation - VRTXAccesswire • 01/23/25
Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits ResearchGlobeNewsWire • 01/22/25
Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 01/16/25
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyAccesswire • 01/15/25
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes TrialsBenzinga • 01/14/25
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/13/25